Arguing that regulators unlawfully expanded the number of medicines eligible for price controls, AstraZeneca Pharmaceuticals has asked the US Court of Appeals for the Fourth Circuit to revive its challenge to the federal government’s implementation of the Medicare drug price negotiation program, part of the Inflation Reduction Act (IRA).
According